2/27
08:00 am
hura
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
2/27
07:30 am
hura
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medium
Report
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
2/24
05:20 pm
hura
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
High
Report
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
2/17
07:45 am
hura
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
High
Report
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
2/12
07:58 am
hura
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/12
07:45 am
hura
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/3
08:03 am
hura
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
2/2
08:11 am
hura
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma [Yahoo! Finance]
Medium
Report
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma [Yahoo! Finance]
2/2
07:45 am
hura
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
High
Report
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
1/24
05:10 am
hura
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
07:18 am
hura
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/15
08:19 am
hura
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone [Yahoo! Finance]
Medium
Report
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone [Yahoo! Finance]
12/15
07:50 am
hura
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
High
Report
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
12/14
01:26 am
hura
TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at
Wall Stre
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at
Wall Stre
12/11
07:50 am
hura
TuHURA Biosciences Provides Corporate Update Following Recent Financing [Yahoo! Finance]
Medium
Report
TuHURA Biosciences Provides Corporate Update Following Recent Financing [Yahoo! Finance]
12/11
07:30 am
hura
TuHURA Biosciences Provides Corporate Update Following Recent Financing
Low
Report
TuHURA Biosciences Provides Corporate Update Following Recent Financing
12/9
09:49 am
hura
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
High
Report
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
12/8
07:50 am
hura
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
Neutral
Report
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition